Assertio Holdings, Inc. is a specialized pharmaceutical company focused on developing and commercializing therapeutic solutions across key medical domains, including neurology, hospital ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.36 · Revenue $32.64M · 1 analysts
Est. EPS $-1.69 · Revenue $105.86M · 1 analysts
Est. EPS $0.19 · Revenue $30.30M · 1 analysts
Est. EPS $0.13 · Revenue $29.30M · 1 analysts
EPS $-2.10 · Revenue $26.49M
EPS $-3.45 · Revenue $124.96M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $118.7M | -5.0% | -26.7% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-30.4M | -40.7% | -58.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +44.9% | -34.5% | -57.5% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -14.5% | +25.9% | -175.2% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -25.6% | -48.2% | -115.5% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-28.2M | -206.7% | +128.6% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -23.7% | -212.3% | +139.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 42.6% | +28.1% | +25.2% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.70x | -3.8% | +7.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $267.0M | -6.2% | -20.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -4.74 vs -5.99 | +20.9% | -2.93 vs -2.10 | -39.4% |
| Revenue Surprise | $118.7M vs $111.4M | +6.6% | $9.9M vs $9.0M | +10.8% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | MCKEE WILLIAM | director | Common Stock | D | 27,936 | — |
| Jun 16, 2026 | MCKEE WILLIAM | director | Stock Option (Right to Buy) | D | 5,415 | $15.15 |
| Jun 16, 2026 | MCKEE WILLIAM | director | Stock Option (Right to Buy) | D | 5,415 | $9.26 |
| Jun 16, 2026 | Schlessinger Sam | officer: EVP, General Counsel | Common Stock | D | 14,738 | — |
| Jun 16, 2026 | Schlessinger Sam | officer: EVP, General Counsel | Restricted Stock Units | D | 25,748 | — |
Operator: Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Assertio Holdings, Inc. Fourth Quarter and Full Year 2025 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star 1 a second time. Thank you. I would now like to turn the conference over to Daniel Santos with Longacre Square Partners. You may begin. Daniel Santos: Thank you. Good afternoon, and thank you all for joining us today to discuss Assertio Holdings, Inc.'s fourth quarter 2025 financial results and business update. The news release covering our results for this period is now available on the Investor page of our website at investor.assertiotx.com. I would encourage you to review the release and tables in conjunction with today's discussion. Please note that during this call, management will make projections and other forward-looking statements regarding our future performance. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in this afternoon's press release as well as Assertio Holdings, Inc.'s filings with the SEC. These and other risks are more fully described in the risk factors section and other sections of our Annual Report on Form 10-Ks and in our Form 10-Q filings. Our actual results may differ materially from those projected in the forward-looking statements, Assertio Holdings, Inc. specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law. With that, I will now turn the call over to Mark L. Reisenauer, Chief Executive Officer. Please go ahead. Mark L. Reisenauer: Well, thank you to everyone for joining us today. Before we dive into our fourth quarter and full year 2025 results, I want to take a moment to share three early observations from my time as CEO and provide some color on where I see opportunities ahead. Since I became CEO in October, I have had the opportunity to meet with team members at every level of our organization and several things have come into focus for me. First, I believe we have a significant revenue opportunity in our core asset, Robodon, which is reflected in our 2026 guidance. Second, we have an experienced commercial operation with strong market access, sales, and contracting capabilities that we can leverage to bring other products to market successfully. And third, our prior strategy of acquiring on-market specialty products is no longer capital efficient or a sustainable strategy to fuel growth. Now let me expand on those points a little bit. Since we acquired Movadon in 2023, the team has worked to …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Mark L. Reisenauer | Chief Executive Officer & Director | USD 1,127,255 | Male | 1966 | Active |
Paul Schwichtenberg | President & Chief Operating Officer | USD 707,248 | Male | 1971 | Active |
Ajay Patel | Executive Vice President & Chief Financial Officer | USD 682,815 | Male | 1984 | Active |
Sam Schlessinger | Executive Vice President & General Counsel | — | Male | 1982 | Active |
Howard J. Franklin | Senior Vice President of Medical | — | — | — | Active |
TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P.
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced the successful completion of its previously announced merger (the “Merger”) with Zydus Lifesciences Ltd. (“Zydus Lifesciences”) pursuant to the terms of the Agreement and Plan of Merger, dated as of May 13, 2026 (the “Merger Agreement”), between, among others, the Company, Zydus Worldwide DMCC, a limited liability company incorporated under the laws of the United Arab Emirate.
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 9, 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
MILWAUKEE, June 08, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Assertio (NASDAQ: ASRT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Zydus.
